Ondansetron
Ondansetron (ondansetron) is a small molecule pharmaceutical. Ondansetron was first approved as Zofran on 1991-01-04. It is used to treat alcoholism in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| chemically-induced disorders | D064419 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Ondansetron (discontinued: Ondansetron, Zofran, Zuplenz)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ondansetron hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER | GSK | N-020403 DISCN | 1995-01-31 | 1 products, RLD |
| ZOFRAN | Sandoz | N-020007 DISCN | 1991-01-04 | 1 products, RLD |
| ZOFRAN PRESERVATIVE FREE | Sandoz | N-020007 DISCN | 1993-12-10 | 1 products, RLD |
| ZOFRAN | Sandoz | N-020103 DISCN | 1992-12-31 | 3 products, RLD |
| ZOFRAN | Sandoz | N-020605 DISCN | 1997-01-24 | 1 products, RLD |
Hide discontinued
Ondansetron
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZUPLENZ | Aquestive Therapeutics | N-022524 DISCN | 2010-07-02 | 2 products, RLD |
| ZOFRAN ODT | Sandoz | N-020781 DISCN | 1999-01-27 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mko melt dose pack | unapproved drug other | 2019-03-04 |
| ondansetron | ANDA | 2025-12-01 |
| ondansetron hcl | ANDA | 2024-12-31 |
| ondansetron hydrochloride | ANDA | 2025-11-14 |
| ondansetron hydrochloride ondansetron hydrochloride | ANDA | 2025-01-27 |
| ondansetron ondansetron hydrochloride | ANDA | 2025-06-12 |
| sumansetron | unapproved drug other | 2023-01-11 |
| zofran | ANDA | 2021-10-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcoholism | EFO_0003829 | D000437 | F10.1 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2405 | Injection, ondansetron hydrochloride, per 1 mg |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
Clinical
Clinical Trials
618 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | 17 | 42 | 62 | 52 | 56 | 225 |
| Nausea | D009325 | — | R11.0 | 15 | 36 | 38 | 45 | 38 | 169 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 6 | 17 | 13 | 37 | 38 | 109 |
| Postoperative pain | D010149 | — | G89.18 | 4 | 2 | 1 | 12 | 35 | 53 |
| Neoplasms | D009369 | — | C80 | 6 | 5 | 9 | 5 | 6 | 30 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 6 | 5 | 3 | 7 | 20 |
| Anesthesia | D000758 | — | — | — | — | 4 | 3 | 10 | 17 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | 2 | 6 | 4 | 6 | 17 |
| Gastroenteritis | D005759 | EFO_1001463 | K52.9 | 1 | 1 | 7 | 4 | 4 | 16 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 9 | 4 | 1 | 1 | 15 |
Show 99 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | 6 | 1 | — | 3 | 12 |
| Syndrome | D013577 | — | — | — | 2 | 4 | — | 2 | 8 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | 2 | — | 2 | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 4 | 1 | — | 1 | 6 |
| Leukemia | D007938 | — | C95 | 2 | 4 | 1 | — | 1 | 6 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 4 | 1 | — | 1 | 6 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 1 | 2 | — | 1 | 6 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 2 | 1 | — | 2 | 5 |
| Laparoscopy | D010535 | — | — | — | — | 2 | — | 3 | 5 |
| Preleukemia | D011289 | — | — | — | 2 | 1 | — | 1 | 4 |
Show 50 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 6 | — | — | 2 | 10 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | 1 | 5 |
| Cocaine-related disorders | D019970 | — | F14 | — | 3 | — | — | 2 | 5 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 4 | — | — | — | 4 |
| Hodgkin disease | D006689 | — | C81 | 2 | 2 | — | — | 1 | 4 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 3 | — | — | 1 | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 3 | — | — | 1 | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 2 | — | — | — | 4 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 3 | — | — | — | 3 |
| Myeloid leukemia | D007951 | — | C92 | — | 3 | — | — | — | 3 |
Show 91 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 17 | — | — | — | 2 | 19 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 4 | — | — | — | 1 | 5 |
| Traumatic brain injuries | D000070642 | — | S06 | 2 | — | — | — | 2 | 4 |
| Brain injuries | D001930 | — | S06.9 | 2 | — | — | — | 2 | 4 |
| Brain concussion | D001924 | — | S06.0 | 1 | — | — | — | 2 | 3 |
| Disease | D004194 | EFO_0000408 | R69 | 3 | — | — | — | — | 3 |
| Covid-19 | D000086382 | — | U07.1 | 1 | — | — | — | — | 1 |
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
| Dyspnea | D004417 | — | R06.0 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | — | 5 | 5 |
| Cardiac surgical procedures | D006348 | — | — | — | — | — | — | 3 | 3 |
| Hernia | D006547 | — | K40-K46 | — | — | — | — | 3 | 3 |
| Male breast neoplasms | D018567 | — | — | — | — | — | — | 3 | 3 |
| Conduction anesthesia | D000765 | — | — | — | — | — | — | 3 | 3 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 2 | 2 |
| Strabismus | D013285 | — | H50.2 | — | — | — | — | 2 | 2 |
| Substance withdrawal syndrome | D013375 | EFO_0005800 | — | — | — | — | — | 2 | 2 |
| Postoperative period | D011184 | — | — | — | — | — | — | 2 | 2 |
Show 70 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ondansetron |
| INN | ondansetron |
| Description | Ondansetron is a member of carbazoles. |
| Classification | Small molecule |
| Drug class | serotonin 5-HT3 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 99614-02-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL46 |
| ChEBI ID | 7773 |
| PubChem CID | 4595 |
| DrugBank | DB00904 |
| UNII ID | 4AF302ESOS (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zuplenz – Par Pharmaceutical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ondansetron
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,302 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,021 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use